EGFR Inhibitor EGFR inhibitor

Cat.No.S0360

EGFR inhibitor, a cell permeable, 4,6-disubstituted pyrimidine compound, is a highly selevtive inhibitor of EGFR kinase with IC50 of 21 nM. EGFR inhibitor directly depolymerizes microtubules and is used as a chemical probe to investigate both the EGFR pathway and microtubule dynamics.
EGFR Inhibitor EGFR inhibitor Chemical Structure

Chemical Structure

Molecular Weight: 413.40

Quality Control

Batch: S036001 DMSO]83 mg/mL]false]Ethanol]2 mg/mL]false]Water]˂1 mg/mL]false Purity: 99.56%
99.56

Chemical Information, Storage & Stability

Molecular Weight 413.40 Formula

C21H18F3N5O

Storage (From the date of receipt) 3 years -20°C powder
CAS No. 879127-07-8 -- Storage of Stock Solutions

Synonyms EGFR-IN-12 Smiles C1CC1C(=O)NC2=CC=CC(=C2)NC3=NC=NC(=C3)NC4=CC=CC(=C4)C(F)(F)F

Solubility

In vitro
Batch:

DMSO : 83 mg/mL (200.77 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 2 mg/mL

Water : ˂1 mg/mL

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
Microtubules [1]
EGFR [1]
(Cell-free assay)
21 nM
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT06118047 Recruiting
Metastatic Colorectal Cancer|Cetuximab|Skin Toxicity
Sun Yat-sen University
August 1 2023 Phase 2
NCT03051880 Unknown status
Drug-Related Side Effects and Adverse Reactions|Epidermal Growth Factor
The Catholic University of Korea
November 2016 Not Applicable
NCT03047863 Unknown status
Drug-Related Side Effects and Adverse Reactions|Epidermal Growth Factor
The Catholic University of Korea
November 2016 Not Applicable
NCT02588261 Terminated
Non-small Cell Lung Cancer (NSCLC)
Astellas Pharma Global Development Inc.|Astellas Pharma Inc
February 11 2016 Phase 3

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Signaling Pathway Map